SIGA Technologies, Inc. (NASDAQ:SIGA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET

Company Participants

Phil Gomez - Chief Executive Officer

Dennis Hruby - Chief Scientific Officer

Dan Luckshire - Chief Financial Officer

Conference Call Participants

Pooya Hemami - Edison Group

Scott Sibley - Equis Group

Operator

Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA does not undertake any obligation to update publicly any forward-looking statements to reflect events or change circumstances after this call. For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including, without limitation, the company's annual report on Form 10-K for the year ended December 31, 2022, and its subsequent report on Form 10-Q and Form 8-K.

I will now turn the call over to your host Phil Gomez, Chief Executive Officer. Mr. Gomez, you may begin sir.

Phil Gomez

Thank you for taking the time to join today's call. Today I'm joined by Dennis Hruby, our Chief Scientific Officer; and Dan Luckshire our CFO. We are pleased to have this opportunity to provide a business, R&D and financial update to our shareholders. We'll then be happy to take questions.

I'd like to start this call by highlighting our expectations for the second half of 2023 that will be achievable based on the work we have done in the first half of the year. In the second half of 2023, we expect the company to generate approximately $113 million of revenue from deliveries of oral TPOXX to the US Strategic National Stockpile and another $30 million to $45 million of revenue from a broad cross-section of domestic and international delivery including the deliveries of oral TPOXX to the Department of Defense, IV TPOXX to the US Strategic National Stockpile and oral TPOXX to international customers.

Based on such revenue expectations, we expect to generate full year 2023 pre-tax operating income of between $90 million and $100 million, representing strong growth over the prior year. These financial expectations reflect successful efforts to diversify our revenue base, anchored by the aforementioned $113 million order from the US Department of Health and Human Services under our 19C contract. The expected deliveries of TPOXX to a broad cross-section of customers is another example of our commitment to consistently meet global demand for TPOXX.